No gastroesophageal adenocarcinoma cell lines with EGFR CNG are available, so to investigate the potential antagonistic interaction between EGFR inhibitors and oxaliplatin and cisplatin, our subsequent experiments focused on ESCC. This evidence concerns the gene EGFR and esophageal squamous cell carcinoma.